We speculate that the high expression of SRXN1 will produce oxidative stress resistance in prostate cancer cells and thus inhibit cancer cell apoptosis, which is not conducive to the survival of radiotherapy patients. This evidence concerns the gene SRXN1 and prostate carcinoma.